2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5552 Application of IWG-ELN 2024 anemia response criteria to patients treated in the phase 3 SIMPLIFY-1 and MOMENTUM trials

Prithviraj Bose, MD, Alessandro Vannucchi, MD2, Steffen Koschmieder, MD3, Shireen Sirhan, MD,FRCP4, Mahshid Azimi, PharmD5, Faith Norster, PhD6, Whitney York, MS7, Pankit Vachhani, MD8
1 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 CRIMM, Hematology Unit, AOU Careggi, University of Florence, Florence, Italy
3 RWTH Aachen University, Aachen, Germany
4 Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
5 GSK, Collegeville, Pennsylvania, United States
6 GSK, London, United Kingdom
7 GSK, Collegeville, Pennsylvania, United States
8 The University of Alabama at Birmingham, Birmingham, United States

Introduction: Decreased hemoglobin (Hb) level and increased transfusion dependence are hallmarks of worsening disease burden and suboptimal treatment response in myelofibrosis (MF). As therapeutic options expand, standardized and clinically meaningful criteria to assess anemia severity and treatment response are needed to evaluate outcomes, enable cross-study comparisons, and inform treatment sequencing. Anemia-related benefits of momelotinib, approved for the treatment of adult patients with intermediate- or high-risk MF and anemia, were initially demonstrated via a prespecified definition of transfusion independence (TI; no transfusions and no Hb <8 g/dL for 12 weeks before week 24). These post hoc analyses apply the revised International Working Group-European LeukemiaNet (IWG-ELN) 2024 criteria (Tefferi A, et al. Blood. 2024;144(17):1813-1820) to the SIMPLIFY-1 and MOMENTUM trials.

Methods: SIMPLIFY-1 (NCT01969838) and MOMENTUM (NCT04173494) were phase 3, randomized, double-blind trials of momelotinib vs ruxolitinib (RUX; Janus kinase [JAK] inhibitor–naive patients) or danazol (DAN; JAK inhibitor–experienced patients), respectively. The IWG-ELN 2024 criteria were applied to all patients with baseline (BL) Hb <10 g/dL, categorizing patients into transfusion-dependent (TD; ≥3 red blood cell [RBC] units in the 12 weeks before randomization) and non-TD (<3 RBC units in the 12 weeks before randomization) anemia subgroups. Major anemia response in both TD and non-TD subgroups was defined as having no transfusions during any rolling 12 weeks in the 24-week treatment period and achieving a rolling 12-week mean Hb increase ≥1.5 g/dL from BL. Minor anemia response was defined as achieving ≥50% reduction in RBC transfusions from BL for any ≥12-week interval during the 24-week treatment period (TD subgroup) or achieving a rolling 12-week mean Hb increase ≥1.0 g/dL from BL and no transfusions (non-TD subgroup).

Results: In SIMPLIFY-1, 63 patients were classified as TD (momelotinib, n=34; RUX, n=29) and 117 as non-TD (momelotinib, n=52; RUX, n=65). In the pooled TD and non-TD momelotinib group, 32/86 patients (37.2%) achieved any anemia response, including 19 (22.1%) with a major response and 13 (15.1%) with a minor response. In the pooled RUX group, 12/94 patients (12.8%) achieved any response, including similar rates for major (n=5; 5.3%) and minor (n=7; 7.4%) responses. Almost half (n=16; 47.1%) of TD patients achieved any response with momelotinib, split evenly across major and minor responses (n=8 each; 23.5%). With RUX, 8 TD patients (27.6%) achieved any response, most of which were minor (n=6; 20.7%), with 2 patients (6.9%) achieving a major response. Among non-TD patients, any, major, and minor responses were achieved by 16 (30.8%), 11 (21.2%), and 5 (9.6%) patients, respectively, with momelotinib and 4 (6.2%), 3 (4.6%), and 1 (1.5%) patients, respectively, with RUX.

In MOMENTUM, 122 patients were classified as TD (momelotinib, n=78; DAN, n=44) and 69 as non-TD (momelotinib, n=48; DAN, n=21). In the pooled TD and non-TD momelotinib group, 64/126 patients (50.8%) achieved any anemia response, with an equal number of major and minor responses (n=32 each; 25.4%). In the pooled DAN group, 17/65 patients (26.2%) achieved any response, including 9 (13.8%) with a major response and 8 (12.3%) with a minor response. In TD patients receiving momelotinib, 39 (50.0%) achieved any response, with 14 (18.0%) achieving a major response and 25 (32.1%) achieving a minor response; 11 TD patients (25.0%) achieved any response with DAN, with similar rates for major (n=5; 11.4%) and minor (n=6; 13.6%) responses. Among non-TD patients, any, major, and minor responses were achieved by 25 (52.1%), 18 (37.5%), and 7 (14.6%) patients, respectively, with momelotinib and 6 (28.6%), 4 (19.0%), and 2 (9.5%) patients, respectively, with DAN.

Conclusions: Using the revised IWG-ELN 2024 criteria, these post hoc analyses of patients with BL anemia in SIMPLIFY-1 and MOMENTUM were consistent with the primary trial analyses’ prespecified TI definition in demonstrating greater anemia benefits with momelotinib vs RUX or DAN. Overall, these findings reinforce the ability of momelotinib to meaningfully improve anemia-related outcomes in MF, including in non-TD patients, which, alongside its established spleen and symptom benefits, further supports its positioning earlier in the treatment pathway and as a potential option for future combination studies.

Prithviraj Bose, MD: Pharma Essentia - Honoraria; GSK - Honoraria; Abbvie - Honoraria; Sumitomo - Honoraria; Incyte - Honoraria; Cogent - Research Funding; GSK - Research Funding; Disc Medicines - Research Funding; Morphosys (Novartis) - Research Funding; Geron - Research Funding; Telios - Research Funding; Bristol Myers Squibb - Research Funding; Incyte - Research Funding; Karyopharm - Research Funding; Kartos Therapeutics - Research Funding; Ajax Therapeutics - Research Funding; Blueprint Medicines - Research Funding; Sumitomo - Research Funding; Janssen - Research Funding; Ionis - Research Funding; Merck - Research Funding; Damora - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Raythera - Consultancy (Includes expert testimony); Pharma Essentia - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Vyne - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Disc Medicines - Consultancy (Includes expert testimony); The University of Texas MD Anderson Cancer Center - Consultancy (Includes expert testimony); Deciphera Pharmaceuticals, LLC - Consultancy (Includes expert testimony); Ionis - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Jubilant - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Morphosys (Novartis) - Consultancy (Includes expert testimony); V6 - Consultancy (Includes expert testimony)